CJC-1295 with DAC
CJC-1295 with DAC
Bionk Peptides delivers high-performance research compounds engineered with uncompromising attention to detail. Every vial is produced to exceed 99% purity and supplied in lyophilised powder form, preserving molecular integrity while ensuring optimal stability and precision in application. Bionk Peptides are commitment to elevated research performance. For laboratory research only. Not for human use.
Couldn't load pickup availability
Description
CJV-1295 with DAC
CJC-1295 with DAC is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH), designed to interact with GHRH receptors and influence growth-hormone signalling pathways. It is commonly investigated within peptide pharmacology and endocrine research.
The DAC (Drug Affinity Complex) modification is designed to extend the peptide's stability and activity by promoting reversible binding to albumin in circulation. This gives CJC-1295 with DAC a substantially longer activity profile than shorter-acting GHRH peptide analogues.
In laboratory research, CJC-1295 with DAC is studied to investigate GHRH receptor signalling, growth-hormone secretion, peptide stability and pharmacokinetics. Experimental models may also examine downstream markers associated with the GH/IGF-1 signalling pathway.
It is primarily of interest in preclinical, biochemical and peptide research, particularly where researchers require a longer-acting GHRH analogue for controlled experimental models. Research use only.
Laboratory Research Data Analysis
- Peptide identity: LC-MS / mass spectrometry
- Purity assessment: HPLC analysis
- Receptor studies: investigation of GHRH receptor interaction
- GH pathway analysis: measurement of growth-hormone-related signalling markers
- IGF-1 pathway research: evaluation of downstream signalling responses
